**Core Concept**
Pegvisomant is a growth hormone receptor antagonist that is used to treat acromegaly, a disorder caused by excessive growth hormone (GH) production. This condition leads to abnormal growth and development, particularly in the hands, feet, and face.

**Why the Correct Answer is Right**
Pegvisomant works by binding to the growth hormone receptor, thereby preventing GH from interacting with its receptor and initiating downstream signaling. This leads to a decrease in insulin-like growth factor 1 (IGF-1) levels, which is a key marker of GH activity. As a result, pegvisomant effectively reduces the symptoms of acromegaly. The drug is particularly useful for patients who do not respond to traditional somatostatin analogs or have severe side effects from these medications.

**Why Each Wrong Option is Incorrect**
**Option A:** Pegvisomant is not approved for the treatment of type 2 diabetes mellitus, as it does not have a significant effect on glucose metabolism.
**Option B:** Pegvisomant is not used to treat growth hormone deficiency in children, as it is not effective in stimulating GH production.
**Option C:** Pegvisomant is not indicated for the treatment of prolactinomas, as it does not have a significant effect on prolactin levels.

**Clinical Pearl / High-Yield Fact**
Pegvisomant is a useful option for patients with acromegaly who have severe symptoms or do not respond to traditional treatments. It is essential to monitor IGF-1 levels regularly to assess the effectiveness of pegvisomant therapy.

**Correct Answer:** C. Acromegaly.